EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Prescription trends in children with pervasive developmental disorders: a claims data-based study in Japan



Prescription trends in children with pervasive developmental disorders: a claims data-based study in Japan



World Journal of Pediatrics 12(4): 443-449



The only drug approved for pervasive developmental disorders (PDD) in Japan is pimozide. Several psychotropic drugs are also prescribed for offlabel use in Japan, but details regarding their prescription and use are largely unknown. The purpose of this study was to clarify the use of drug treatment in Japanese children with PDD. Data were extracted from claims data from the Japan Medical Data Center for children younger than 18 years of age who were newly diagnosed with PDD (International Classification of Diseases version 10 codes: F84) from 2005 to 2010 (total of 3276 patients as of 2010). The prescription rates were presented as the percentage of PDD patients who were prescribed each drug. Prior to 2010, the prescription rates for atypical antipsychotics, other antipsychotics, psychostimulants, all other central nervous system drugs, anticovnvulsants, non-barbiturates, and Parkinson's disease/syndrome drugs significantly increased among the Anatomical Therapeutic Chemical classifications defined as the "nervous system" (trend P≤0.02). The prescription rate for risperidone consistently increased, reaching 6.9% in 2010 (trend P<0.0001), the highest rate of the surveyed drugs among the antipsychotics. The prescription rate for aripiprazole also increased (trend P<0.0001), reaching 1.9% in 2010. The prescription rate for pimozide showed no annual changes, with a low rate of 0.4% in 2010. Compared with pimozide, the prescription rates for risperidone, aripiprazole and other psychotropic drugs have increased. Because safety data for these drugs in Japanese children are sparse, there is a need for future safety evaluations of these drugs in Japanese children.

(PDF same-day service: $19.90)

Accession: 058610380

Download citation: RISBibTeXText

PMID: 27286689

DOI: 10.1007/s12519-016-0036-8



Related references

Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan. Clinical Rheumatology 34(5): 949-956, 2016

Sensory integrative-based occupational therapy and functional outcomes in young children with pervasive developmental disorders: a single-subject study. American Journal of Occupational Therapy 53(2): 207-213, 1999

Validation of an interview-based rating scale developed in Japan for pervasive developmental disorders. Research in Autism Spectrum Disorders 6(4): 1265-1272, 2012

Brief report: A theory-of-mind-based social-cognition training program for school-aged children with pervasive developmental disorders: an open study of its effectiveness. Journal of Autism and Developmental Disorders 36(4): 567-571, 2006

Frequency of pervasive developmental disorders and supports for workers with pervasive developmental disorders in workplaces: a field survey of psychiatrists well acquainted with occupational practices. Sangyo Eiseigaku Zasshi 54(1): 29-36, 2012

Empirically based phenotypic profiles of children with pervasive developmental disorders: interpretation in the light of the DSM-5. Journal of Autism and Developmental Disorders 43(8): 1784-1797, 2014

Comparison of data-collection methods in a behavioral intervention program for children with pervasive developmental disorders: a replication. Journal of Applied Behavior Analysis 42(4): 827-832, 2010

How unspecified are disorders of children with a pervasive developmental disorder not otherwise specified? A study of social problems in children with PDD-NOS and ADHD. European Child & Adolescent Psychiatry 9(3): 168-179, 2000

Guidelines for medical examination of children with mental retardation in pediatric clinics which are specialized for developmental disorders - Recommendation based on the current selection and usefulness of diagnostic examinations for children with mental retardation and/or pervasive developmental disorder. No To Hattatsu 36(3): 224-229, 2004

A Novel Method of Building Functional Brain Network Using Deep Learning Algorithm with Application in Proficiency Detection. International Journal of Neural Systems: 1850015-1850015, 2018

Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. Journal of Autism and Developmental Disorders 35(3): 387-391, 2005

A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology 191(1): 141-147, 2006

The incidence and prevalence of pervasive developmental disorders: a Danish population-based study. Psychological Medicine 34(7): 1339-1346, 2005

Differentiating developmental language disorders from pervasive developmental disorders in young children. Journal of Clinical & Experimental Neuropsychology 10(1): 80, 1988